Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

There was a positive trend towards exposure-response for PFS [ 113 ].

also in 6,779 other papers

For larotrectinib, no relationship between exposure and toxicity was described in the approval report ( n = 66); in exposure-toxicity analyses for entrectinib there is a weak trend between higher exposure and frequency of serious AEs, although this was not significant after correction for gender in the analysis ( n = 263).

also in 834 other papers

FMS-like Tyrosine Kinase 3 Receptor (FLT3) Inhibitors For midostaurin, lower exposure showed a trend towards increased risk of death in patients with acute myeloid leukemia in combination with daunorubicin and cytarabine, but this was not statistically significant, as described in the approval report ( n = 360) [ 101 ].

also in 33,237 other papers